Alcoi

Researchers are evaluating the effectiveness of camizestrant compared to standard endocrine therapy in patients with early breast cancer that is estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-). These patients have an intermediate or high risk of cancer recurrence and have already completed local treatments such as surgery and possibly chemotherapy, alongside at least 2 years and up to 5 years of standard adjuvant endocrine therapy. The study is a Phase III, open-label trial designed to assess outcomes over a long term. Participants will be randomly assigned to receive either camizestrant, an oral selective estrogen receptor degrader, or one of several standard endocrine therapies including tamoxifen, anastrozole, letrozole, or exemestane, administered according to local approved guidelines. The treatment duration for both groups is planned to last 60 months. Eligible patients may have previously used CDK4/6 inhibitors, and the study will specifically include those with intermediate or high risk of recurrence as determined by clinical and biological markers. During the study, participants will be monitored for up to 10 years from the last patient's randomization to evaluate invasive breast cancer-free survival. Additional outcomes include invasive disease-free survival, distant relapse-free survival, overall survival, safety, and clinical outcome assessments. The study involves ongoing assessments of health status, treatment effects, and safety to determine the long-term benefits and risks of camizestrant compared to standard therapies.

Researchers are conducting an observational, multicenter epidemiological study to collect information from medical records of patients diagnosed with advanced metastatic or unresectable melanoma in Spain. The study focuses on patients with stage III or IV melanoma at their first diagnosis after January 8, 2018, aiming to describe the characteristics of this patient group without applying any experimental treatments. Participants will receive treatments determined by routine clinical practice, with no interventions or changes mandated by the study protocol. Treatment decisions are made independently of study inclusion, and no additional diagnostic or follow-up procedures beyond standard care will be applied. Patients may have received prior treatments at different hospitals, and their information will be updated across centers with appropriate consent. Throughout the study, researchers will gather data from medical records to characterize the patient population and their treatments. The main outcome measure is the sample characteristics at baseline. Patients will be tracked via assigned codes and follow-up is conducted as per usual clinical procedures, with efforts made to maintain updated information when patients transfer between centers. Participation involves consenting to data collection without additional study-related medical procedures.

Researchers are conducting an observational study called SOGUG-PRINCIS to collect and analyze data on the effectiveness of drugs recently approved for treating genitourinary tumors under routine clinical practice in Spain. This national, multicenter study includes both retrospective patient data and prospective follow-up, aiming to validate real-world outcomes compared to those reported in phase III clinical trials. The study covers cancers originating in the kidney, ureter, bladder, prostate, testicle, urethra, penis, and seminal vesicles. The study observes patients treated with drugs such as darolutamide combined with androgen deprivation therapy and docetaxel, adjuvant nivolumab after surgical removal of urothelial carcinoma, and enfortumab vedotin. All treatments follow their approved dosing and administration guidelines in standard clinical practice. New subprojects may be added as new drugs gain funding approval by the Spanish National Health System, with each subproject focusing on specific primary endpoints. Participants' involvement includes treatment decisions made independently from the study, with data collected afterward to assess outcomes. Researchers will track progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after treatment initiation. The study also serves as a registry for genitourinary cancer treatments funded nationally, supporting long-term evaluation of drug effectiveness in real-world settings.

Researchers are studying patients diagnosed with cancer who experience a venous or arterial thromboembolic event, either symptomatic or found incidentally. These events may occur within a month before the cancer diagnosis or at any time after it. This observational, epidemiological, multicenter study aims to gather detailed data about these thromboembolic episodes in cancer patients. The study does not involve any interventions or treatments but collects information about the thromboembolic event, including its location, vessel of origin, diagnosis type, and characteristics of cancer at the time of the event. It also records the timing between cancer diagnosis and the thromboembolism. Participants are observed over time, with data collected at baseline and a 12-month follow-up visit to assess patient status and treatment details. Participants provide consent and undergo imaging confirmation of thromboembolic events using techniques like Doppler echocardiography or CT angiography. Researchers track multiple outcome measures such as tumor classification, primary tumor presence, and treatment administered for cancer. The study monitors participants for a year to record their clinical situation and gather comprehensive information on cancer-associated thrombosis.

This observational, multicenter study focuses on patients diagnosed with lung cancer and other thoracic tumors. It aims to improve treatment and prognosis by exploring patient data related to the expression of markers that predict responses to chemotherapy and molecular inhibitors. The study reflects a commitment to individualized treatment and understanding the epidemiology of thoracic tumors in Spain, addressing the high mortality and variability in diagnosis and treatment. The study collects information both retrospectively and prospectively from clinical histories of patients treated by thoracic surgeons and medical oncologists. It investigates epidemiological and therapeutic factors associated with thoracic tumors, including lung cancer, to support strategies like multidisciplinary care and early diagnosis. There are no interventions or treatments assigned, as this is an observational registry gathering comprehensive real-world data. Participants will have their clinical data reviewed to describe characteristics of lung cancer and other thoracic tumors over up to 10 years. The study aims to explore the epidemiology and treatment approaches, supporting future improvements in care. There is no age or gender restriction, and data collection includes both patients receiving active treatment and those under palliative care. The study duration, follow-up, and specific assessments are based on patient records and available medical information.